566 related articles for article (PubMed ID: 25536015)
1. Adaptation of Leishmania donovani to cutaneous and visceral environments: in vivo selection and proteomic analysis.
McCall LI; Zhang WW; Dejgaard K; Atayde VD; Mazur A; Ranasinghe S; Liu J; Olivier M; Nilsson T; Matlashewski G
J Proteome Res; 2015 Feb; 14(2):1033-59. PubMed ID: 25536015
[TBL] [Abstract][Full Text] [Related]
2. Leishmaniasis in Turkey: Visceral and cutaneous leishmaniasis caused by Leishmania donovani in Turkey.
Özbilgin A; Harman M; Karakuş M; Bart A; Töz S; Kurt Ö; Çavuş İ; Polat E; Gündüz C; Van Gool T; Özbel Y
Acta Trop; 2017 Sep; 173():90-96. PubMed ID: 28587839
[TBL] [Abstract][Full Text] [Related]
3. Screening Leishmania donovani complex-specific genes required for visceral disease.
Zhang WW; Matlashewski G
Methods Mol Biol; 2015; 1201():339-61. PubMed ID: 25388124
[TBL] [Abstract][Full Text] [Related]
4. Leishmanization revisited: immunization with a naturally attenuated cutaneous Leishmania donovani isolate from Sri Lanka protects against visceral leishmaniasis.
McCall LI; Zhang WW; Ranasinghe S; Matlashewski G
Vaccine; 2013 Feb; 31(10):1420-5. PubMed ID: 23219435
[TBL] [Abstract][Full Text] [Related]
5. In vivo selection for Leishmania donovani miniexon genes that increase virulence in Leishmania major.
Zhang WW; Matlashewski G
Mol Microbiol; 2004 Nov; 54(4):1051-62. PubMed ID: 15522086
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vivo expression of amastigote up regulated Leishmania genes in three different forms of Leishmaniasis.
Sharma P; Gurumurthy S; Duncan R; Nakhasi HL; Salotra P
Parasitol Int; 2010 Jun; 59(2):262-4. PubMed ID: 19963076
[TBL] [Abstract][Full Text] [Related]
7. Expression of a Leishmaniadonovani nucleotide sugar transporter in Leishmaniamajor enhances survival in visceral organs.
Zhang WW; Chan KF; Song Z; Matlashewski G
Exp Parasitol; 2011 Dec; 129(4):337-45. PubMed ID: 21978449
[TBL] [Abstract][Full Text] [Related]
8. Pure protein from Leishmania donovani protects mice against both cutaneous and visceral leishmaniasis.
Rachamim N; Jaffe CL
J Immunol; 1993 Mar; 150(6):2322-31. PubMed ID: 8450215
[TBL] [Abstract][Full Text] [Related]
9. Evidence that a naturally occurring single nucleotide polymorphism in the RagC gene of Leishmania donovani contributes to reduced virulence.
Lypaczewski P; Zhang WW; Matlashewski G
PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009079. PubMed ID: 33621241
[TBL] [Abstract][Full Text] [Related]
10. An In-depth Proteomic Map of Leishmania donovani Isolate from Post Kala-azar Dermal Leishmaniasis (PKDL) Patient.
Routaray CB; Kumar A; Sundar S; Sathe G; Pawar H; Pai K
Acta Parasitol; 2022 Jun; 67(2):687-696. PubMed ID: 35020128
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the A2 gene locus in Leishmania donovani and Leishmania major and its control over cutaneous infection.
Zhang WW; Mendez S; Ghosh A; Myler P; Ivens A; Clos J; Sacks DL; Matlashewski G
J Biol Chem; 2003 Sep; 278(37):35508-15. PubMed ID: 12829719
[TBL] [Abstract][Full Text] [Related]
12. Tissue Specific Dual RNA-Seq Defines Host-Parasite Interplay in Murine Visceral Leishmaniasis Caused by Leishmania donovani and Leishmania infantum.
Forrester S; Goundry A; Dias BT; Leal-Calvo T; Moraes MO; Kaye PM; Mottram JC; Lima APCA
Microbiol Spectr; 2022 Apr; 10(2):e0067922. PubMed ID: 35384718
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases.
Al-Abdely HM; Graybill JR; Loebenberg D; Melby PC
Antimicrob Agents Chemother; 1999 Dec; 43(12):2910-4. PubMed ID: 10582881
[TBL] [Abstract][Full Text] [Related]
14. Dermotropic Leishmania donovani in Sri Lanka: visceralizing potential in clinical and preclinical studies.
Kariyawasam KKGDUL; Selvapandiyan A; Siriwardana HVYD; Dube A; Karunanayake P; Senanayake SASC; Dey R; Gannavaram S; Nakhasi HL; Karunaweera ND
Parasitology; 2018 Apr; 145(4):443-452. PubMed ID: 29113609
[TBL] [Abstract][Full Text] [Related]
15. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
[TBL] [Abstract][Full Text] [Related]
16. An imported case of cutaneous leishmaniasis caused by Leishmania (Leishmania) donovani in Japan.
Ito K; Takahara M; Ito M; Oshiro M; Takahashi K; Uezato H; Imafuku S
J Dermatol; 2014 Oct; 41(10):926-8. PubMed ID: 25228325
[TBL] [Abstract][Full Text] [Related]
17. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
18. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis.
Al-Abdely HM; Graybill JR; Bocanegra R; Najvar L; Montalbo E; Regen SL; Melby PC
Antimicrob Agents Chemother; 1998 Oct; 42(10):2542-8. PubMed ID: 9756753
[TBL] [Abstract][Full Text] [Related]
19. Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease?
McMahon-Pratt D; Alexander J
Immunol Rev; 2004 Oct; 201():206-24. PubMed ID: 15361243
[TBL] [Abstract][Full Text] [Related]
20. Leishmania donovani: impairment of the cellular immune response against recombinant ornithine decarboxylase protein as a possible evasion strategy of Leishmania in visceral leishmaniasis.
Yadav A; Amit A; Chaudhary R; Chandel AS; Mahantesh V; Suman SS; Singh SK; Dikhit MR; Ali V; Rabidas V; Pandey K; Kumar A; Das P; Bimal S
Int J Parasitol; 2015 Jan; 45(1):33-42. PubMed ID: 25449949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
